Radiotherapy and Oncology, 15 (1989) 397–400
Elsevier

AUTHOR INDEX

Adam, I., see Flower, M. A., 345
Algarra, S. M., see Calvo, F. A., 133
Ang, K. K., see Thames, H. D., 49
Aristei, C., see Latini, P., 227
Arriagada, R. and Auguier, A.
Difficulties in evaluating non-randomized studies (Editorial), 307
Arráns, R., see Sánchez, F., 259
Ashby, M. A., see Campana, F., 321
Auguier, A., see Arriagada, R., 307
Azinovic, I., see Calvo, F. A., 133

Bartelink, H., see Begg, A. C., 79
Bartelink, HG., see Stewart, F. A., 93
Baume, D., see Cosset, J. M., 151
Beaumier, P. L., see Lavie, E., 295
Begg, A. C., Bohlken, S.and Bartelink, H.
The effect of cisplatin on the reapir of radiation damage in RIF1 mouse tumours in vivo, 79
Benhamou, E., see Cosset, J. M., 151
Bennett, M. H., see Dische, S., 19
Bentzen, S. M., Thames, H. D. and Overgaard, M.
Latent-time estimation for late cutaneous and subcutaneous radiation in a single-follow-up clinical study, 267
Blanc-Jouvan, F., see Nagy-Mignotte, H., 333
Blosser, E. B., see Maughan, R. L., 125
Blosser, G. F., see Maughan, R. L., 125
Blosser, H. G., see Maughan, R. L., 125
Blott, P. and Trott, K. R.
The effect of actinomycin D on split-dose recovery and repopulation in jejunal crypt cells in vivo, 73
Bohlken, S., see Begg, A. C., 79
Bolla, M., see Nagy-Mignotte, H., 333
Brahme, A., Källman, P. and Lind, B. K.
Optimization of proton and heavy ion therapy using an adaptive inversion algorithm, 189
Brambilla, C., see Nagy-Mignotte, H., 333
Briot, E., see Cosset, J. M., 151
Brodzinsky, L., see Lavie, E., 295
Brown, J. M., see Horsman, M. R., 103

Calvo, F. A., Algarra, S. M., Azinovic, I., Santos, M., Escude, L., Hernández, J. L., Zornoza, G. and Voltas, J.
Intraoperative radiotherapy for recurrent and/or residual colorectal cancer, 133
Campana, F., Fourquet, A., Ashby, M. A., Sastre, X., Jullien, D., Schlienger, P., Labib, A. and Vilcoq, J. R.
Presentation of axillary lymphadenopathy without detectable breast primary (To N1b breast cancer): experience at Institut Curie, 321
Carlson, J., see Wollin, M., 285
Checcaglini, F., see Latini, P., 227
Chetty, U., see Rodger, A., 243
Corbett, P. J., see Rodger, A., 243
Cosset, J. M. and Shank, B.
Reply to: TBI schedules prior to bone marrow transplantation: requirements for comparison (Letter to the Editor), 211
Cosset, J. M., Baume, D., Pico, J. L., Shank, B., Girinski, T., Benhamou, E., Briot, E., Malaise, E., Hayat, M. and Dutreix, J.
Single dose versus hyperfractionated total body irradiation before allogeneic bone marrow transplantation: a non-randomized comparative study of 54 patients at the Institut Gustave-Roussy, 151
Courdi, A., see Tubiana, M., 1

Dale, R. G.
Time-dependent tumour repopulation factors in linear-quadratic equations – implications for treatment strategies,371
Deibel, F. C., see Kim, T. H., 341
Denekamp, J., see Hill, S. A., 39;
Dische, S., Saunders, M. I., Bennett, M. H., Wilson, G. D. and McNally, N. J.
Cell proliferation and differentiation in squamous cancer, 19
Doane, K., see Kantorowitz, D. A., 141
Dube, P., see Lusinchi, A., 313
Dutreix, J.
Expression of the dose rate effect in clinical curietherapy, 25
Dutreix, J., see Cosset, J. M., 151
Dvoretsky, P. M., see Kantorowitz, D. A., 141

Elbelli, M. A., see Flower, M. A., 345
Eschwege, F., see Lusinchi, A., 313
Escude, L., see Calvo, F. A., 133

FitzGerald, T. J., see Wollin, M., 285
Flower, M. A., Schlesinger, T., Hinton, P. J., Adam, I., Masoomi, A. M., Elbelli, M. A., Ott, R. J., McCready, V. R. and Harmer, C. L.
Radiation dose assessment in radioiodine therapy. 2. Practical implementation using quantitative scanning and PET, with initial results on thyroid carcinoma, 345
Fourquet, A., see Campana, F., 321

Gerbi, B. J., see Kim, T. H., 341
Girinski, T., see Cosset, J. M., 151
Greenberger, J. S., see Wollin, M., 285

Hallén, C., Skåre, N.-G. and Underskog, I.
Betamethasone-dixyrazine combination versus high-dose metoclopramide as antiemetic treatment in doxorubicin and cisplatin chemotherapy 161, Sorbe, B.
Harmer, C. L., see Flower, M. A., 345
Hayat, M., see Cosset, J. M., 151
Hellström, I., see Lavie, E., 295
Hellström, K. E., see Lavie, E., 295
Hendry, J. H., see Thames, H. D., 49
Hernández, J. L., see Calvo, F. A., 133
Hill, S. A. and Denekamp, J.
An experimental study of tumour size and radiosensitivity: analysis by regrowth delay, 39
Hinton, P. J., see Flower, M. A., 345
Hirst, D. G. and Wood, P. J.
Altered radiosensitivity in a mouse carcinoma after administration of, clofibrate and bezafibrate, 55
Hopewell, J. W., see Yeung, T. K., 275
Horsman, M. R., Wood, P. J. and Brown, J. M.
Misonidazole chemosensitization of EMT6 spheroids to melphalan, 103
Jullien, D., see Campana, F., 321

Kaasa, S., Matsekassa, A. and Lund, E.
Prognostic factors for patients with inoperable non-small cell lung cancer, limited disease, 235
Kantorowitz, D. A., Poulter, C. A., Rubin, P., Patterson, E., Sobel, S. H., Sischy, B., Dvoretsky, P. M., Michalak, W. A. and Doane, K.
Treatment of breast cancer with segmental mastectomy alone or segmental mastectomy plus radiation, 141
Keane, T. J. and Van Dyk, J.
TBI schedules prior to bone marrow transplantation: requirements for comparison (Letter to the Editor), 207
Kelland, L. R. and Tonkin, K. S.
The effect of 3-aminobenzamide in the radiation response of three human cervix carcinoma xenografts, 363
Khan, F. M., see Kim, T. H., 341
Kim, T. H., Gerbi, B. J., Deibel, F. C., Priest, J. R. and Khan, F. M.
An afterloading brachytherapy device utilizing thermoplastic material, 341
Kolodié, H., see Nagy-Mignotte, H., 333
Kunkler, I., see Lusinchi, A., 313
Källman, P., see Brahme, A., 189

Labib, A., see Campana, F., 321
Latini, P., Maranzano, E., Ricci, S., Aristei, C., Checcaglini, F., Panizza, B. M. and Perrucci, E.
Role of radiotherapy in metastatic spinal cord compression: preliminary results from a prospective trial, 227
Lavie, E., Beaumier, P. L., Brodzinsky, L., Hellström, K. E. and Hellström, I.
Evaluation of L6, an anti-carcinoma murine monoclonal antibody, in tumor- bearing nude mice, 295
Lind, B. K., see Brahme, A., 189
Longcope, C., see Wollin, M., 285
Luboinski, B., see Lusinchi, A., 313
Lund, E., see Kaasa, S., 235
Lundbeck, F., Ulso, N. and Overgaard, J.
Cystometric evaluation of early and late irradiation damage to the mouse urinary bladder, 383
Lusinchi, A., Dube, P., Wibault, P., Kunkler, I., Luboinski, B. and Eschwege, F.
Radiation therapy in the treatment of early glottic carcinoma: the experience of Villejuif, 313

Madurga, G., see Sánchez, F., 259
Malaise, E., see Cosset, J. M., 151
Maranzano, E., see Latini, P., 227
Masoomi, A. M., see Flower, M. A., 345
Mastekassa, A., see Kaasa, S., 235
Maughan, R. L., Blosser, G. F., Blosser, E. B., Blosser, H. G. and Powers, W. E.
Transmission measurements in multi-rod arrays: a design study for a multi-rod collimator, 125
McCready, V. R., see Flower, M. A., 345
McNally, N. J., see Dische, S., 19
Meertens, H.

A comparison of dose calculations at points around an intracavitary cervix applicator, 199
Menon, M., see Wollin, M., 285
Michalak, W. A., see Kantorowitz, D. A., 141
Moore, J. V., see Thames, H. D., 49
Moro, D., see Nagy-Mignotte, H., 333

Nagy-Mignotte, H., Bolla, M., Wuyam, B., Blanc-Jouvan, F., Moro, D., Brambilla, C., Paramelle, B., Vincent, F., Kolodié, H. and Vrousos, C.
Sequential combination of 5-fluoroacil, cisplatinum and irradiation in unresectable non-small cell lung cancer, 333

O'Donoghue, J. A.
Comparison of the prediction of the LQ and CRE models for normal tissue damage due to biologically targeted radiotherapy with exponentially decaying dose rates, 359
Ott, R. J., see Flower, M. A., 345
Oussoren, Y., see Stewart, F. A., 93
Overgaard, J., see Lundbeck, F., 383
Overgaard, M., see Bentzen, S. M., 267

Panizza, B. M., see Latini, P., 227
Paramelle, B., see Nagy-Mignotte, H., 333
Patterson, E., see Kantorowitz, D. A., 141
Peacock, J. H., see Steel, G. G., 63
Perrucci, E., see Latini, P., 227
Pico, J. L., see Cosset, J. M., 151
Poulter, C. A., see Kantorowitz, D. A., 141
Powers, W. E., see Maughan, R. L., 125
Priest, J. R., see Kim, T. H., 341

Reale, F., see Wollin, M., 285
Ricci, S., see Latini, P., 227
Rodger, A., Corbett, P. J. and Chetty, U.
Lactation after breast conserving therapy, including radiation therapy, for early breast cancer, 243
Rubin, P., see Kantorowitz, D. A., 141

Sakakeeny, M. A., see Wollin, M., 285
Salminen, E.
Split-course radiotherapy for urinary bladder cancer, 327
Sánchez, F., Madurga, G. and Arráns, R.
Neutron measurements around an 18 MV linac, 259
Santos, M., see Calvo, F. A., 133
Santucci, M. A., see Wollin, M., 285
Sastre, X., see Campana, F., 321
Saunders, M. I., see Dische, S., 19
Schlesinger, T., see Flower, M. A., 345
Schlienger, P., see Campana, F., 321
Shank, B., see Cosset, J. M., 151
Shank, B., see Cosset, J. M., 211ë
Simmonds, R. H., see Yeung, T. K., 275
Sischy, B., see Kantorowitz, D. A., 141
Skåre, N.-G., see Hallén, C., Sorbe, B.
Sobel, S. H., Kantorowitz, D. A., 141
Steel, G. G. and Peacock, J. H.
Why are some human tumours more radiosensitive than others?, 63
Stewart, F. A., Oussoren, Y. and Bartelink, H.
The influence of cisplatin on the response of mouse kidneys to multifraction irradiation, 93

Taylor, J. M. G., see Vegesna, V., 115
Thames, H. D., Hendry, J. H., Moore, J. V., Ang, K. K. and Travis, E. L.
The high steepness of dose-response curves for late-responding normal tissues, 49
Thames, H. D., see Bentzen, S. M., 267
Thames, H. D., see Turesson, I., 169
Tonkin, K. S., see Kelland, L. R., 363
Travis, E. L., see Thames, H. D., 49
Trott, K. R., see Blott, P., 73
Tubiana, M. and Courdi, A.
Cell proliferation kinetics in human solid tumors: relation to probability of metastatic dissemination and long-term survival, 1
Turesson, I.
The progression rate of late effects in normal tissue and its impact on dose-response relationships, 217
Turesson, I. and Thames, H. D.
Repair capacity and kinetics of human skin during fractionated radiotherapy: erythema, desquamation, and telangiectasia after 3 and 5 year's follow-up, 169

UIso, N., see Lundbeck, F., 383
Underskog, I., see Hallén, C., Sorbe, B.

Van Dyk, J., see Keane, T. J., 207
Vegesna, V., Withers, H. R. and Taylor, J. M. G.
Repair kinetics of mouse lung, 115,
Vilcoq, J. R., see Campana, F., 321
Vincent, F., see Nagy-Mignotte, H., 333
Visser, A. G.
An intercomparison of the accuracy of computer planning systems for brachytherapy, 245
Voltas, J., see Calvo, F. A., 133
Vrousos, C., see Nagy-Mignotte, H., 333

Wibault, P., see Lusinchi, A., 313
Wilson, G. D., see Dische, S., 19

Withers, H. R., see Vegesna, V., 115
Wollin, M., FitzGerald, T. J., Santucci, M. A., Menon, M., Longcope, C., Reale, F., Carlson, J., Sakakeeny, M. A. and Greenberger, J. S.
Radiosensitivity of human prostate cancer and malignant melanoma cell lines, 285
Wood, P. J., see Hirst, D. G., 55
Wood, P. J., see Horsman, M. R., 103
Wuyam, B., see Nagy-Mignotte, H., 333

Yeung, T. K., Simmonds, R. H. and Hopewell, J. W.
A functional assessment of the relative cardiotoxicity of adriamycin and epirubicin in the rat, 275

Zornoza, G., see Calvo, F. A., 133

Radiotherapy and Oncology, 15 (1989) 401–402
Elsevier

SUBJECT INDEX

3-Aminobenzamide
  radiation response, in vivo, 363
Actinomycin in D-radiation interaction, 73
Activation detector, 259
Acute and late bladder damage, 383
Acute radiation effect, 169
Adriamycin, 275
Animal model, 383
Antibody fragments, 295
Antiemetics, 161
Antilipidaemics, 55
Aquaplast, 341

Betamethasone, 161
Bifunctional modification, 295
Biologically targeted radiotherapy, 359
Bone marrow transplantation, 151
Brachytherapy
  dose calculations, 199
  treatment planning, 199
  quality assurance, 199
  accuracy, 199
Brachytherapy, 245
Brachytherapy, 341
Breast cancer, 1, 141, 243, 321
Bromodeoxyuridine, 19

Cardiac output, 275
Cardiotoxicity, 275
Cell lung carcinoma, non-squamous, 333
Cell repopulation, 73
Cellular differentiation, 19
Cervix carcinoma, 363
Chemosensitization, 103
Chemotherapy-induced nausea, 161
Cisplatin, 79
Clinical radiobiology, 267
Collimation, 125
Colorectal cancer, 133:
Combined chemotherapy/radiotherapy, 333
Combined modalities, 79
Computer planning, accuracy, 245
Conservation therapy, 243
Curietherapy
  dose rate, 25
Cystometry, 383
Cytometry, 1

Desferrioxamine B, 295
cis-Diamminedichloroplatinum(II), 93
Dixyrazine, 161
Dose fractionation, 115
Dose fractionation, 169
Dose response curves, 49
3-D planning, 189

Early glottic carcinoma, 313
EMT6 spheroids, 103
Epirubicin, 275

Flow cytometry, 1
Fractionation in radiotherapy, 151
Fractionation, 49, 217, 267
Fractionation, 93

Haemoglobin, 55
Human cell kinetics, 19
Human tumours
  recovery, 63
  repair, 63

Immunohistology, 19
In vivo dosimetry, 345
Inoperable non-small cell lung cancer, 235
Intraoperative radiotherapy, 133
Inverse therapy planning, 189
Irradiation, 383
Irregular fields, 125
Isoeffect dose computation, 25

Jejunum, 73
L_6 monoclonal antibody, 295
Lactation, 243
Late normal tissue damage, 217
Late radiation effect, 169
Late radiation effects in normal tissue, 267
Linear-quadratic equations, 371
Linear-quadratic isoeffect model, 115
LQ model, 267
Lumpectomy, 141
Lumph node, 321

Malignant melanoma, 285
Medical linear accelerator, 259
Melphalan, 103

Metastatic spinal cord compression, 227
Metoclopramide, high-dose, 161
Misonidazole, 103
Mixture model, 267
Montecarlo method, 259
Mouse kidney, 93
Mouse tumours, 79

Neutron measurement, 259
Neutrons, 125
Normal tissue, 49

Orbital cancer, 341
Overall time effect, 169

Photons, 125
Prognostic factor, 235
Prognostic factors, 1
Progressive radiation damage in patients, 217
Prostate cancer, 285
Proton therapy planning, 189

Quality of life, 227, 235
Quantitative scanning, PET, 345

Radiation pneumonitis, 115
Radiation response, 79
Radiation therapy, 313
Radiation, 55
Radioimmunotherapy
  dose-rate effects, 359
  isoeffect models, 359
Radioiodine therapy
  Practical implementation, 345
Radiolocalization/imaging, 295
Radiosensitivity, 63
Radiotherapy
  local control, 327
  survival, 327
Radiotherapy, late effects, 49
Repair capacity, 169
Repair kinetic, 169
Repair kinetics, 115

Scanned beams, 189
Segmental mastectomy, 141
Sequential disaggregation procedure, 103
Skin, 169
S-phase fraction, 1
Split-course radiotherapy, 327
Split-dose recovery, 73
Squamous cancer, 19

Thymidine labelling index, 1
Total body irradiation, 151
Tumour repopulation
  accelerated hyperfractionation, 371
  prottracted therapy, 371
  treatment strategies, 371
Tumour size and radiosensitivity
  regrowth delay, 39
  experimental study, 39
Tumours, 55

Urinary bladder cancer, 19

X-rays, 93